Foundation Medicine Announces Clinical Cancer Genomics Collaboration with Celgene Corporation

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc., a personalized cancer diagnostics company that aims to bring comprehensive cancer genome analysis to routine clinical care, today announced a strategic collaboration with Celgene Corporation (NASDAQ: CELG). The collaboration – Foundation Medicine’s second major pharmaceutical company alliance in 2011 – is focused on using Foundation Medicine’s comprehensive clinical cancer genomics test in ongoing trials of Celgene drug candidates. The test in development will be used to facilitate faster recruitment of target patient populations and for broad genetic characterization of all trial enrollees which may help to identify those patients most likely to respond to Celgene drug candidates. Financial details of the agreement were not disclosed.